Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy

Clinical Infectious Diseases

Volumn 50, Issue 10, 2010, Pages 1415-1418

  Aurpibul, Linda ^a   Puthanakit, Thanyawee ^a   Sirisanthana, Thira ^a   Sirisanthana, Virat ^b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIRETROVIRUS AGENT; EFAVIRENZ; MEASLES MUMPS RUBELLA VACCINE; NEVIRAPINE;

ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEASLES; MUMPS; PRIORITY JOURNAL; REVACCINATION; RUBELLA;

ANTI-HIV AGENTS; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; MALE; MEASLES; MUMPS; RUBELLA; TIME FACTORS;

EID: 77951814475     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/652150     Document Type: Article

References (15)

1. World Health Organization, UNICEF. Review of national immunization coverage, 1980-2008. Geneva: World Health Organization, 2008. http://www.who.int/immunization-monitoring/data/tha.pdf.
2. Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. Annual epidemiological surveillance report 2008. http:// epid.moph.go.th/Annual/Annual%202551/Part1-51/Annual-MenuPart1-51/ Annual-MenuPart1-51.html.
3. Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med 2006; 7: 467-470. (Pubitemid 44269814)
4. Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination, in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45: 637-642. (Pubitemid 47328647)
5. Ratnam S, Gadag V, West R, et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 1995; 33: 811-815.
6. Chunharas A, Lolekha S. Immunity in children with measles vaccine: determining the proper age for booster dose. Thai J Pediatr 1996; 35: 259-263.
7. Kim SS, Han HW, Go U, Chung HW. Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity. Vaccine 2004; 23: 290-297. (Pubitemid 39463044)
8. Lima M, Succi RCM, Santos AMND, Weckx LY, Moraes-Pinto MI. Rubella immunization in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2004; 23: 604-607.
9. Aurpibul L, Puthanakit T, Kanjanavanit S, Sirisanthana T, Sirisanthana V. Measles outbreak in an orphanage: HIV-infected children on antiretroviral therapy are still at risk. Pediatr Inf Dis J 2010; 29: 167-169.
10. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118: e315-e322. (Pubitemid 46085372)
11. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics 2003; 111: e641-e644.
12. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008; 197: 950-956. (Pubitemid 351590022)
13. Pebody RG, Gay NJ, Hesketh LM, et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 2002; 20: 1134-1140.
14. Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccinees-a longitudinal study. Vaccine 2006; 24: 2594-2601. (Pubitemid 43290391)
15. Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 1996; 15: 687-692.